filed with the Securities and Exchange Commission on January 16, 2026 by the Federated Hermes Project and Trade Finance Tender Fund (the “Fund”) relating to the Fund’s offer to repurchase common shares of beneficial interest of the Fund (including Institutional Shares and Service Shares, the “Shares”) from its shareholders (“Shareholders”) on the terms and subject to the conditions set forth in the Offer to Repurchase and the related Letter of Transmittal in an aggregate amount of up to $50,389,853.64 (the “Offer”) and constitutes the final

✦Federated Hermes Project and Trade Finance Fund is repurchasing up to $50.4 million of its own shares, reducing share count and potentially improving per-share metrics for remaining shareholders.

20549 SCHEDULE TO (Rule 13e-4) TENDER OFFER STATEMENT PURSUANT TO SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Final Amendment) Federated Hermes Project and Trade Finance Tender Fund (Name of Issuer) Federated Hermes Project and Trade Finance Tender Fund (Name of Person(s) Filing Statement (Issuer)) Common Shares of Beneficial Interest (Title of Class of Securities) Institutional Shares 31424D104 Service Shares 31424D401 (CUSIP Number of Class of Securities) Peter J. Pittsburgh, PA 1

✦Federated Hermes is repurchasing its own shares at a set price, reducing share count and potentially boosting per-share earnings while signaling management confidence in undervaluation.

Expires: February 17, 2026.

✦FHI is repurchasing its own shares at a fixed price through February 2026, which should reduce share count and boost earnings per share if profitability remains stable.

Expires: May 14, 2026.

✦BK's issuer tender offer signals management confidence in undervaluation and will reduce share count, benefiting remaining shareholders through increased EPS and lower capital structure costs.

May 14, 2026 Notice Date The deadline by which you must properly notify the Fund in writing if you wish to tender Shares for repurchase (unless extended by the Fund to a later date subsequently designated by the Fund).* The Fund will not accept any repurchase request received by it or its designated agent after the Notice Date. May 14, 2026 Expiration Date The deadline by which, if you previously provided proper written notice to the Fund of your desire to tender Shares, you may properly notify the Fund of your desire to withdraw such tender request.* June 11, 2026 Acceptance Dat

✦FHI's issuer tender offer allows shareholders to sell shares back at a set price by May 14, providing liquidity but potentially signaling management expects undervaluation or needs capital restructuring.

☐ amendment to Schedule 13D under Rule 13d-2.   Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐   If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:   ☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer) ☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)             SCHEDULE TO (Amendment No.

✦ZCAR's issuer tender offer amendment suggests the company is buying back its own shares, potentially signaling management believes stock is undervalued and aiming to reduce share count and boost earnings per share.

Offer price: $80.00 per share.

✦Wix management believes the stock is undervalued at $80, so this buyback will reduce share count and boost earnings-per-share while returning capital to remaining shareholders.

Offer price: $80.00 per share.

20549 Schedule TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) AIP Alternative Lending Fund P (Name of Subject Company (Issuer)) AIP Alternative Lending Fund P (Names of Filing Persons (Offeror and Issuer)) SHARES OF BENEFICIAL INTEREST (Title of Class of Securities) N/A (CUSIP Number of Class of Securities) Kara Fricke, Esq.

20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AIP Alternative Lending Fund P (Name of Subject Company (Issuer)) AIP Alternative Lending Fund P (Name of Filing Person(s) (Issuer)) SHARES OF BENEFICIAL INTEREST (Title of Class of Securities) N/A (CUSIP Number of Class of Securities) Kara Fricke, Esq. Morgan Stanley Investment Management Inc.

20549 Schedule TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) AIP Alternative Lending Fund A (Name of Subject Company (Issuer)) AIP Alternative Lending Fund A (Names of Filing Persons (Offeror and Issuer)) SHARES OF BENEFICIAL INTEREST (Title of Class of Securities) N/A (CUSIP Number of Class of Securities) Kara Fricke, Esq.

20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AIP Alternative Lending Fund A (Name of Subject Company (Issuer)) AIP Alternative Lending Fund A (Name of Filing Person(s) (Issuer)) SHARES OF BENEFICIAL INTEREST (Title of Class of Securities) N/A (CUSIP Number of Class of Securities) Kara Fricke, Esq. Morgan Stanley Investment Management Inc.

Offer price: $4.35 per share. Expires: March 23, 2026.

(Name of Subject Company and Filing Persons (Issuer)) Series C Non-Convertible Redeemable Preferred Stock (Title of Class of Securities) 293904702 (CUSIP Number of Class of Securities) Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc.

(Name of Subject Company and Filing Persons (Issuer)) Series C Non-Convertible Redeemable Preferred Stock (Title of Class of Securities) 293904702 (CUSIP Number of Class of Securities) Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc.

Expires: April 23, 2026.

(Name of Subject Company and Filing Person (Issuer) and Name of Filing Person (Offeror)) 0.00% Convertible Senior Notes due 2030 (Title of Class of Securities) 23248V AC9 (CUSIP Number of Class of Securities) Bruce Byrd, Esq. Executive Vice President and General Counsel Palo Alto Networks, Inc.

Ramirez Practus, LLP 11300 Tomahawk Creek Pkwy, Ste 310 Leawood, KS 66211 1-917-805-1818 September 4, 2025 (Date Tender Offer First Published, Sent or Given to Security Holders) i [X] Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Expires: April 17, 2026.

(Name of Subject Company and Filing Persons (Issuer)) Series C Non-Convertible Redeemable Preferred Stock (Title of Class of Securities) 293904702 (CUSIP Number of Class of Securities) Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc.

(Name of Subject Company and Filing Persons (Issuer)) Series C Non-Convertible Redeemable Preferred Stock (Title of Class of Securities) 293904702 (CUSIP Number of Class of Securities) Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc.

Offer price: $27.00 per share. Expires: April 10, 2026.

(Name of Subject Company and Filing Persons (Issuer)) Series C Non-Convertible Redeemable Preferred Stock (Title of Class of Securities) 293904702 (CUSIP Number of Class of Securities) Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Enzon Pharmaceuticals, Inc.

1) North Haven Private Income Fund LLC (Name of Subject Company (Offeror and Issuer)) North Haven Private Income Fund LLC (Name of Filing Persons (Issuer)) Class S Units (Title of Class of Securities) N/A (CUSIP Number of Class of Securities) Michael Occi Orit Mizrachi MS Capital Partners Adviser Inc. Carter Dechert LLP One International Place, 40th Floor 100 Oliver Street Boston, MA 02110-2605 Check the box if the filing relates solely to preliminary communications made before commencement of a

Collins Partners Group Growth, LLC 1114 Avenue of the Americas, 37th Floor New York, NY 10036 (212) 908-2600 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Filing Person(s)) With a copy to: Joshua B. Faegre Drinker Biddle Reath LLP One Logan Square, Ste.

Collins Partners Group Private Equity Fund, LLC 1114 Avenue of the Americas, 37th Floor New York, NY 10036 (212) 908-2600 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Filing Person(s)) With a copy to: Joshua B. Faegre Drinker Biddle Reath LLP One Logan Square, Ste.